{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:28Z","timestamp":1794047428659,"version":"4.8.0"},"reference-count":58,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"11","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Drug resistance underpins poor outcomes in many malignancies including refractory and relapsed acute myeloid leukemia (R\/R AML). Glucuronidation is a common mechanism of drug inactivation impacting many AML therapies, e.g., cytarabine, decitabine, azacytidine and venetoclax. In AML cells, the capacity for glucuronidation arises from increased production of the UDP-glucuronosyltransferase 1A (UGT1A) enzymes. UGT1A elevation was first observed in AML patients who relapsed after response to ribavirin, a drug used to target the eukaryotic translation initiation factor eIF4E, and subsequently in patients who relapsed on cytarabine. UGT1A elevation resulted from increased expression of the sonic-hedgehog transcription factor GLI1. Vismodegib inhibited GLI1, decreased UGT1A levels, reduced glucuronidation of ribavirin and cytarabine, and re-sensitized cells to these drugs. Here, we examined if UGT1A protein levels, and thus glucuronidation activity, were targetable in humans and if this corresponded to clinical response. We conducted a phase II trial using vismodegib with ribavirin, with or without decitabine, in largely heavily pre-treated patients with high-eIF4E AML. Pre-therapy molecular assessment of patients\u2019 blasts indicated highly elevated UGT1A levels relative to healthy volunteers. Among patients with partial response, blast response or prolonged stable disease, vismodegib reduced UGT1A levels, which corresponded to effective targeting of eIF4E by ribavirin. In all, our studies are the first to demonstrate that UGT1A protein, and thus glucuronidation, are targetable in humans. These studies pave the way for the development of therapies that impair glucuronidation, one of the most common drug deactivation modalities. Clinicaltrials.gov: NCT02073838.<\/jats:p>","DOI":"10.3324\/haematol.2023.282791","type":"journal-article","created":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T04:25:34Z","timestamp":1679545534000},"page":"2946-2958","source":"Crossref","is-referenced-by-count":19,"title":["Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory\/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine"],"prefix":"10.3324","volume":"108","author":[{"given":"Sarit","family":"Assouline","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadwiga","family":"Gasiorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana","family":"Culjkovic-Kraljacic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eftihia","family":"Cocolakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Zakaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Szlachtycz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine L.B.","family":"Borden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,3,23]]},"reference":[{"key":"53410","doi-asserted-by":"crossref","unstructured":"de Lima M, Roboz GJ, Platzbecker U, Craddock C, Ossenkoppele G. AML and the art of remission maintenance. Blood Rev. 2021; 49:100829.","DOI":"10.1016\/j.blre.2021.100829"},{"key":"53411","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Rausch CR, Benton C. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J Hematol. 2018; 93(3):401-407.","DOI":"10.1002\/ajh.25000"},{"key":"53412","doi-asserted-by":"crossref","unstructured":"DiNardo CD, Jonas BA, Pullarkat V. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020; 383(7):617-629.","DOI":"10.1056\/NEJMoa2012971"},{"key":"53413","doi-asserted-by":"crossref","unstructured":"Maiti A, Rausch CR, Cortes JE. Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. 2021; 106(3):894-898.","DOI":"10.3324\/haematol.2020.252569"},{"key":"53414","doi-asserted-by":"crossref","unstructured":"Mangan JK, Luger SM. Salvage therapy for relapsed or refractory acute myeloid leukemia. Ther Adv Hematol. 2011; 2(2):73-82.","DOI":"10.1177\/2040620711402533"},{"key":"53415","doi-asserted-by":"crossref","unstructured":"Silva WFD, Rosa LID, Seguro FS. Salvage treatment for refractory or relapsed acute myeloid leukemia: a 10-year singlecenter experience. Clinics (Sao Paulo). 2020; 75:e1566.","DOI":"10.6061\/clinics\/2020\/e1566err"},{"key":"53416","doi-asserted-by":"crossref","unstructured":"Zahreddine H, Borden KL. Mechanisms and insights into drug resistance in cancer. Front Pharmacol. 2013; 4:28.","DOI":"10.3389\/fphar.2013.00028"},{"key":"53417","doi-asserted-by":"crossref","unstructured":"Zahreddine HA, Culjkovic-Kraljacic B, Assouline S. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. Nature. 2014; 511(7507):90-93.","DOI":"10.1038\/nature13283"},{"key":"53418","doi-asserted-by":"crossref","unstructured":"Ueda K, Hosokawa M, Iwakawa S. Cellular uptake of decitabine by equilibrative nucleoside transporters in HCT116 cells. Biol Pharm Bull. 2015; 38(8):1113-1119.","DOI":"10.1248\/bpb.b14-00622"},{"key":"53419","doi-asserted-by":"crossref","unstructured":"Hummel-Eisenbeiss J, Hascher A, Hals PA. The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells. Mol Pharmacol. 2013; 84(3):438-450.","DOI":"10.1124\/mol.113.086801"},{"key":"53420","doi-asserted-by":"crossref","unstructured":"Wohnsland A, Hofmann WP, Sarrazin C. Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev. 2007; 20(1):23-38.","DOI":"10.1128\/CMR.00010-06"},{"key":"53421","doi-asserted-by":"crossref","unstructured":"Borden KL. When will resistance be futile?. Cancer Res. 2014; 74(24):7175-7180.","DOI":"10.1158\/0008-5472.CAN-14-2607"},{"key":"53422","doi-asserted-by":"crossref","unstructured":"Landmann H, Proia DA, He S. UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib. Cell Death Dis. 2014; 5(9):e1411.","DOI":"10.1038\/cddis.2014.378"},{"key":"53423","doi-asserted-by":"crossref","unstructured":"Gruber M, Bellemare J, Hoermann G. Overexpression of uridine diphosphoglucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. Blood. 2013; 121(7):1175-1183.","DOI":"10.1182\/blood-2012-08-447359"},{"key":"53424","doi-asserted-by":"crossref","unstructured":"Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol. 2000; 40:581-616.","DOI":"10.1146\/annurev.pharmtox.40.1.581"},{"key":"53425","doi-asserted-by":"crossref","unstructured":"Zahreddine HA, Culjkovic-Kraljacic B, Gasiorek J, Duchaine J, Borden KLB. GLI1-inducible glucuronidation targets a broad spectrum of drugs. ACS Chem Biol. 2019; 14(3):348-355.","DOI":"10.1021\/acschembio.8b01118"},{"key":"53426","doi-asserted-by":"crossref","unstructured":"Rowland A, Miners JO, Mackenzie PI. The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol. 2013; 45(6):1121-1132.","DOI":"10.1016\/j.biocel.2013.02.019"},{"key":"53427","doi-asserted-by":"crossref","unstructured":"Allain EP, Rouleau M, Levesque E, Guillemette C. Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progression. Br J Cancer. 2020; 122(9):1277-1287.","DOI":"10.1038\/s41416-019-0722-0"},{"key":"53428","doi-asserted-by":"crossref","unstructured":"Ghram M, Morris G, Culjkovic-Kraljacic B. The eukaryotic translation initiation factor eIF4E reprogrammes the splicing machinery and drives alternative splicing. EMBO J. 2023; 42(7):e110496.","DOI":"10.15252\/embj.2021110496"},{"key":"53429","doi-asserted-by":"crossref","unstructured":"Topisirovic I, Guzman ML, McConnell MJ. Aberrant eukaryotic translation initiation factor 4E-dependent mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. Mol Cell Biol. 2003; 23(24):8992-9002.","DOI":"10.1128\/MCB.23.24.8992-9002.2003"},{"key":"53430","doi-asserted-by":"crossref","unstructured":"Assouline S, Culjkovic-Kraljacic B, Bergeron J. A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E. Haematologica. 2015; 100(1):e7-9.","DOI":"10.3324\/haematol.2014.111245"},{"key":"53431","doi-asserted-by":"crossref","unstructured":"Assouline S, Culjkovic B, Cocolakis E. Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin. Blood. 2009; 114(2):257-260.","DOI":"10.1182\/blood-2009-02-205153"},{"key":"53432","doi-asserted-by":"crossref","unstructured":"Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL. eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3'UTR. J Cell Biol. 2005; 169(2):245-256.","DOI":"10.1083\/jcb.200501019"},{"key":"53433","doi-asserted-by":"crossref","unstructured":"Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL. eIF4E is a central node of an RNA regulon that governs cellular proliferation. J Cell Biol. 2006; 175(3):415-426.","DOI":"10.1083\/jcb.200607020"},{"key":"53434","doi-asserted-by":"crossref","unstructured":"Topisirovic I, Siddiqui N, Lapointe VL. Molecular dissection of the eukaryotic initiation factor 4E (eIF4E) export-competent RNP. EMBO J. 2009; 28(8):1087-1098.","DOI":"10.1038\/emboj.2009.53"},{"key":"53435","doi-asserted-by":"crossref","unstructured":"Culjkovic-Kraljacic B, Fernando TM, Marullo R. Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. Blood. 2016; 127(7):858-868.","DOI":"10.1182\/blood-2015-05-645069"},{"key":"53436","doi-asserted-by":"crossref","unstructured":"Borden KL. The eukaryotic translation initiation factor eIF4E wears a &quot;cap&quot; for many occasions. Translation (Austin). 2016; 4(2):e1220899.","DOI":"10.1080\/21690731.2016.1220899"},{"key":"53437","doi-asserted-by":"crossref","unstructured":"Davis MR, Delaleu M, Borden KLB. Nuclear eIF4E stimulates 3\u2019-end cleavage of target RNAs. Cell Rep. 2019; 27(5):1397-1408.e4.","DOI":"10.1016\/j.celrep.2019.04.008"},{"key":"53438","doi-asserted-by":"crossref","unstructured":"Culjkovic-Kraljacic B, Skrabanek L, Revuelta MV. The eukaryotic translation initiation factor eIF4E elevates steady-state m(7)G capping of coding and noncoding transcripts. Proc Natl Acad Sci U S A. 2020; 117(43):26773-26783.","DOI":"10.1073\/pnas.2002360117"},{"key":"53439","doi-asserted-by":"crossref","unstructured":"Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL. Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap. Proc Natl Acad Sci U S A. 2004; 101(52):18105-18110.","DOI":"10.1073\/pnas.0406927102"},{"key":"53440","doi-asserted-by":"crossref","unstructured":"Kentsis A, Volpon L, Topisirovic I. Further evidence that ribavirin interacts with eIF4E. RNA. 2005; 11(12):1762-1766.","DOI":"10.1261\/rna.2238705"},{"key":"53441","doi-asserted-by":"crossref","unstructured":"Kraljacic BC, Arguello M, Amri A, Cormack G, Borden K. Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens. Leukemia. 2011; 25(7):1197-1200.","DOI":"10.1038\/leu.2011.57"},{"key":"53442","doi-asserted-by":"crossref","unstructured":"Volpon L, Osborne MJ, Zahreddine H, Romeo AA, Borden KL. Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate. Biochem Biophys Res Commun. 2013; 434(3):614-619.","DOI":"10.1016\/j.bbrc.2013.03.125"},{"key":"53443","doi-asserted-by":"crossref","unstructured":"Culjkovic-Kraljacic B, Fernando TM, Marullo R. Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. Blood. 2016; 127(7):858-868.","DOI":"10.1182\/blood-2015-05-645069"},{"key":"53444","doi-asserted-by":"crossref","unstructured":"Pettersson F, Yau C, Dobocan MC. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res. 2011; 17(9):2874-2884.","DOI":"10.1158\/1078-0432.CCR-10-2334"},{"key":"53445","doi-asserted-by":"crossref","unstructured":"Pettersson F, del Rincon SV, Emond A. Genetic and pharmacolgic inhibition of eIF4E reduces breast cancer cell migration, invasion and metastasis. Cancer Res. 2015; 75(6):1102-1112.","DOI":"10.1158\/0008-5472.CAN-14-1996"},{"key":"53446","doi-asserted-by":"crossref","unstructured":"Zahreddine H, Kraljacic-Culjkovic B, Edmond A. The eukaryotic translation initiation factor eIF4E harnesses hyaluronan production to drive its malignant activity. Elife. 2017; 6:e29830.","DOI":"10.7554\/eLife.29830"},{"key":"53447","doi-asserted-by":"crossref","unstructured":"Bollmann F, Fechir K, Nowag S. Human inducible nitric oxide synthase (iNOS) expression depends on chromosome region maintenance 1 (CRM1)- and eukaryotic translation initiation factor 4E (elF4E)-mediated nucleocytoplasmic mRNA transport. Nitric Oxide. 2013; 30:49-59.","DOI":"10.1016\/j.niox.2013.02.083"},{"key":"53448","doi-asserted-by":"crossref","unstructured":"Shi F, Len Y, Gong Y. Ribavirin inhibits the activity of mTOR\/eIF4E, ERK\/Mnk1\/eIF4E signaling pathway and synergizes with tyrosine kinase inhibitor imatinib to impair Bcr-Abl mediated proliferation and apoptosis in Ph+ leukemia. PLoS One. 2015; 10(8):e0136746.","DOI":"10.1371\/journal.pone.0136746"},{"key":"53449","doi-asserted-by":"crossref","unstructured":"Zismanov V, Attar-Schneider O, Lishner M, Heffez Aizenfeld R, Tartakover Matalon S, Drucker L. Multiple myeloma proteostasis can be targeted via translation initiation factor eIF4E. Int J Oncol. 2015; 46(2):860-870.","DOI":"10.3892\/ijo.2014.2774"},{"key":"53450","doi-asserted-by":"crossref","unstructured":"Volpin F, Casaos J, Sesen J. Use of an anti-viral drug, ribavirin, as an anti-glioblastoma therapeutic. Oncogene. 2017; 36(21):3037-3047.","DOI":"10.1038\/onc.2016.457"},{"key":"53451","doi-asserted-by":"crossref","unstructured":"Wang G, Li Z, Li Z. Targeting eIF4E inhibits growth, survival and angiogenesis in retinoblastoma and enhances efficacy of chemotherapy. Biomed Pharmacother. 2017; 96:750-756.","DOI":"10.1016\/j.biopha.2017.10.034"},{"key":"53452","doi-asserted-by":"crossref","unstructured":"Volpon L, Culjkovic-Kraljacic B, Osborne MJ. Importin 8 mediates m7G cap-sensitive nuclear import of the eukaryotic translation initiation factor eIF4E. Proc Natl Acad Sci U S A. 2016; 113(19):5263-5268.","DOI":"10.1073\/pnas.1524291113"},{"key":"53453","doi-asserted-by":"crossref","unstructured":"Dunn LA, Fury MG, Sherman EJ. Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA\/IVB human papillomavirus-associated oropharyngeal squamous cell cancer. Head Neck. 2017; 40(2):233-241.","DOI":"10.1002\/hed.24938"},{"key":"53454","doi-asserted-by":"crossref","unstructured":"Kosaka T, Maeda T, Shinojima T, Nagata H, Mizuno R, Mototsugu O. A clinical study to evaluate the efficacy and safety of docetaxal with ribavirin in patients with progressive castration resistant prostate cancer who have previously received docetaxol alone. J Clin Oncol. 2017; 35(15 Suppl):e14010.","DOI":"10.1200\/JCO.2017.35.15_suppl.e14010"},{"key":"53455","doi-asserted-by":"crossref","unstructured":"Zimmerman EI, Huang M, Leisewitz AV, Wang Y, Yang J, Graves LM. Identification of a novel point mutation in ENT1 that confers resistance to Ara-C in human T cell leukemia CCRF-CEM cells. FEBS Lett. 2009; 583(2):425-429.","DOI":"10.1016\/j.febslet.2008.12.041"},{"key":"53456","doi-asserted-by":"crossref","unstructured":"Schroeder T, Rautenberg C, Kr\u00fcger WH. Decitabine as salvage therapy for relapse of AML and MDS after allogeneic stem cell transplantation - a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Blood. 2016; 128(22):3446.","DOI":"10.1182\/blood.V128.22.3446.3446"},{"key":"53457","doi-asserted-by":"crossref","unstructured":"Mori K, Hiraoka O, Ikeda M. Adenosine kinase is a key determinant for the anti-HCV activity of ribavirin. Hepatology. 2013; 58(4):1236-1244.","DOI":"10.1002\/hep.26421"},{"key":"53458","doi-asserted-by":"crossref","unstructured":"Osborne MJ, Coutinho de Oliveira L, Volpon L, Zahreddine HA, Borden KLB. Overcoming drug resistance through the development of selective inhibitors of UDP-glucuronosyltransferase enzymes. J Mol Biol. 2019; 431(2):258-272.","DOI":"10.1016\/j.jmb.2018.11.007"},{"key":"53459","doi-asserted-by":"crossref","unstructured":"Dellinger RW, Matundan HH, Ahmed AS, Duong PH, Meyskens FL Jr. Anti-cancer drugs elicit re-expression of UDP-glucuronosyltransferases in melanoma cells. PLoS One. 2012; 7(10):e47696.","DOI":"10.1371\/journal.pone.0047696"},{"key":"53460","doi-asserted-by":"crossref","unstructured":"Guillemette C, Levesque E, Rouleau M. Pharmacogenomics of human uridine diphospho-glucuronosyltransferases and clinical implications. Clin Pharmacol Ther. 2014; 96(3):324-339.","DOI":"10.1038\/clpt.2014.126"},{"key":"53461","doi-asserted-by":"crossref","unstructured":"Pricl S, Cortelazzi B, Dal Col V. Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol. 2015; 9(2):389-397.","DOI":"10.1016\/j.molonc.2014.09.003"},{"key":"53462","doi-asserted-by":"crossref","unstructured":"Wellbrock J, Latuske E, Kohler J. Expression of hedgehog pathway mediator GLI represents a negative prognostic marker in human acute myeloid leukemia and its inhibition exerts antileukemic effects. Clin Cancer Res. 2015; 21(10):2388-2398.","DOI":"10.1158\/1078-0432.CCR-14-1059"},{"key":"53463","doi-asserted-by":"crossref","unstructured":"Bixby D, Noppeney R, Lin TL. Safety and efficacy of vismodegib in relapsed\/refractory acute myeloid leukaemia: results of a phase Ib trial. Br J Haematol. 2019; 185(3):595-598.","DOI":"10.1111\/bjh.15571"},{"key":"53464","doi-asserted-by":"crossref","unstructured":"Hong DS, Kurzrock R, Oh Y. A phase 1 dose escalation, pharmacokinetic, and pharmacodynamic evaluation of eIF-4E antisense oligonucleotide LY2275796 in patients with advanced cancer. Clin Cancer Res. 2011; 17(20):6582-6591.","DOI":"10.1158\/1078-0432.CCR-11-0430"},{"key":"53465","doi-asserted-by":"crossref","unstructured":"Suarez M, Blyth GT, Mina AA. Inhibitory effects of tomivosertib in acute myeloid leukemia. Oncotarget. 2021; 12(10):955-966.","DOI":"10.18632\/oncotarget.27952"},{"key":"53466","doi-asserted-by":"crossref","unstructured":"Joshi S, Platanias LC. Mnk kinase pathway: cellular functions and biological outcomes. World J Biol Chem. 2014; 5(3):321-333.","DOI":"10.4331\/wjbc.v5.i3.321"},{"key":"53467","doi-asserted-by":"crossref","unstructured":"Papadopoulos E, Jenni S, Kabha E. Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G. Proc Natl Acad Sci U S A. 2014; 111(31):E3187-3195.","DOI":"10.1073\/pnas.1410250111"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282791\/75453","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282791\/76210","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11033\/75453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:03:46Z","timestamp":1794045826000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.282791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":58,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.282791","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,23]]}}}